Cargando…

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention

Without prevention or screening options available, ovarian cancer is the most lethal malignancy of the female reproductive tract. High-grade serous ovarian cancer (HGSOC) is the most common histologic subtype, and the role of germline BRCA1/2 mutation in predisposition and prognosis is established....

Descripción completa

Detalles Bibliográficos
Autores principales:	Karakasis, Katherine, Burnier, Julia V., Bowering, Valerie, Oza, Amit M., Lheureux, Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862980/ https://www.ncbi.nlm.nih.gov/pubmed/27242959 http://dx.doi.org/10.3389/fonc.2016.00119

Ejemplares similares

Ovarian cancer treatment: The end of empiricism?
por: Lheureux, Stephanie, et al.
Publicado: (2015)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
por: Madariaga, Ainhoa, et al.
Publicado: (2019)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
por: Bhat, Gita, et al.
Publicado: (2020)

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
por: Colombo, Ilaria, et al.
Publicado: (2023)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
por: Yang, S. Y. Cindy, et al.
Publicado: (2018)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer
por: Lee, Yeh Chen, et al.
Publicado: (2019)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
por: George, Sophia H. L., et al.
Publicado: (2016)

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers
por: Kasherman, Lawrence, et al.
Publicado: (2022)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
por: McMullen, Michelle, et al.
Publicado: (2020)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers
por: Lesueur, Fabienne, et al.
Publicado: (2018)

Updates on systemic therapy for cervical cancer
por: Gopu, Paul, et al.
Publicado: (2021)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

Opportunities and Challenges of the Human Microbiome in Ovarian Cancer
por: Cheng, Huiyan, et al.
Publicado: (2020)

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country
por: Lourenção, Marina, et al.
Publicado: (2022)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers
por: Sahnane, Nora, et al.
Publicado: (2023)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study
por: Tian, Chunqiao Q., et al.
Publicado: (2013)

Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
por: Oosthuizen, Jaco, et al.
Publicado: (2021)

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different
por: Burgess, Melissa, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2021)

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges
por: Bukłaho, Patrycja Aleksandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uigje96ib4mec0rle0dbiqvk6m